483 related articles for article (PubMed ID: 23587496)
21. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
[TBL] [Abstract][Full Text] [Related]
22. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
23. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
Ringrose JS; Sanche SE; Taylor-Gjevre RM
Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
[TBL] [Abstract][Full Text] [Related]
24. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
25. Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab.
Cruz AT; Karam LB; Orth RC; Starke JR
Pediatr Infect Dis J; 2014 Jul; 33(7):779-81. PubMed ID: 24469071
[TBL] [Abstract][Full Text] [Related]
26. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
[TBL] [Abstract][Full Text] [Related]
27. Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?
Cabriada JL; Ruiz-Zorrilla R; Barrio J; Atienza R; Huerta A; Rodríguez-Lago I; Bernal A; Herrero C
Turk J Gastroenterol; 2018 May; 29(3):292-298. PubMed ID: 29755013
[TBL] [Abstract][Full Text] [Related]
28. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
Taxonera C; Ponferrada Á; Riestra S; Bermejo F; Saro C; Martín-Arranz MD; Cabriada JL; Barreiro-de Acosta M; de Castro ML; López-Serrano P; Barrio J; Suarez C; Iglesias E; Argüelles-Arias F; Ferrer I; Marín-Jiménez I; Hernández-Camba A; Bastida G; Van Domselaar M; Martínez-Montiel P; Olivares D; Rivero M; Fernandez-Salazar L; Nantes Ó; Merino O; Alba C; Gisbert JP;
J Crohns Colitis; 2018 Nov; 12(11):1270-1279. PubMed ID: 30052856
[TBL] [Abstract][Full Text] [Related]
29. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.
Chang B; Park HY; Jeon K; Ahn JK; Cha HS; Koh EM; Kang ES; Koh WJ
Clin Rheumatol; 2011 Dec; 30(12):1535-41. PubMed ID: 21556777
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
31. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP
Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986
[TBL] [Abstract][Full Text] [Related]
32. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment.
Sauzullo I; Mengoni F; Scrivo R; Valesini G; Potenza C; Skroza N; Marocco R; Lichtner M; Vullo V; Mastroianni CM
Int J Tuberc Lung Dis; 2010 Jul; 14(7):834-40. PubMed ID: 20550765
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of latent tuberculosis infection (LTBI) before anti-TNF-alpha treatment--the tuberculin skin test is useful.
Goujon C; Nosbaum A; Bensaid B; Rozières A; Nicolas JF; Bérard F
Eur J Dermatol; 2012; 22(5):701-2. PubMed ID: 23032063
[No Abstract] [Full Text] [Related]
35. The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients.
Abreu C; Almeida F; Ferraz R; Dias CC; Sarmento A; Magro F
Dig Liver Dis; 2016 Dec; 48(12):1438-1443. PubMed ID: 27599804
[TBL] [Abstract][Full Text] [Related]
36. Performance of QuantiFERON TB gold test compared with the tuberculin skin test for detecting latent tuberculosis infection in lung and heart transplant candidates.
Mardani M; Farshidpour M; Nekoonam M; Varahram F; Najafizadeh K; Mohammadi N; Sharifkashani B; Gachkar L; Farokhzad B; Droudinia A; Javanmard P; Tabarsi P
Exp Clin Transplant; 2014 Apr; 12(2):129-32. PubMed ID: 24702145
[TBL] [Abstract][Full Text] [Related]
37. Tuberculosis during TNF-α inhibitor therapy, despite screening.
Hofland RW; Thijsen SF; Verhagen MA; Schenk Y; Bossink AW
Thorax; 2013 Nov; 68(11):1079-80. PubMed ID: 23598710
[TBL] [Abstract][Full Text] [Related]
38. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
Sánchez-Moya AI; Dauden E
J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
[TBL] [Abstract][Full Text] [Related]
40. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
